



Current Status and Future Directions in Non-Small Cell Lung Cancer Therapy

Guest Editors:

Dr. Fei Zhou

Department of Medical Oncology,
Shanghai Pulmonary Hospital,
Thoracic Cancer Institute, Tongji
University School of Medicine,
Shanghai 200433, China

Dr. Xiaoxia Chen

Department of Medical Oncology,
Shanghai Pulmonary Hospital,
Thoracic Cancer Institute, Tongji
University School of Medicine,
Shanghai 200433, China

Deadline for manuscript
submissions:

closed (20 October 2023)

Message from the Guest Editors

Dear Colleagues,

The therapeutic strategies for non-small cell lung cancer have evolved rapidly in recent years. For patient with targetable oncogenes, including EGFR mutations, ALK/ROS1/RET fusions, targeted therapy with small molecular tyrosine kinase inhibitors, have demonstrated superior efficacy over classical chemotherapy. Great progress has also been achieved in some rare oncogenes, including BRAF^{V600E} mutations, HER2 mutations, EGFR 20ins, NTRK fusions et al. On the other hand, for patients without oncogenic drivers, immune checkpoint inhibitors, targeting the PD-1/PD-L1 axis, either as monotherapy or in combination with chemotherapy, have been the standard of care and have resulted in long-term survival in a subset of patients. Despite these advancements, acquired resistance inevitably occurs. A better understanding of the mechanisms of resistance to therapy is essential to further expand the survival benefits. In the future, we believe novel targets and novel agents (i.e. bispecific antibody, antibody–drug conjugate) will help translating this malignancy into a “chronic disease”.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department,
University Hospital Strasbourg,
67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and
Critical Care Medicine, University
of Tokyo, Tokyo 113-8655, Japan

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's (JCM)* staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us

Journal of Clinical Medicine Editorial
Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jcm
jcm@mdpi.com
[X@JCM_MDPI](https://twitter.com/JCM_MDPI)